Teva Pharmaceutical Industries Limited (NYSE: TEVA) upgraded to Buy with price target $80 by Goldman
Goldman upgraded Teva Pharmaceutical Industries Limited (NYSE: TEVA) to Buy with price target $80 with today's price
of $70.72. Goldman rated Teva Pharmaceutical Industries Limited (NYSE: TEVA) to Neutral with price target $52 on 03/19/2014, when the price was $50.22. Teva Pharmaceutical Industries Limited's stock price gained 41% since then.
Teva Pharmaceutical Industries Limited
(Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson?s disease and respiratory products. Teva?s active pharmaceutical ingredient business provides vertical integration to Teva?s own pharmaceutical production and sells to third party manufacturers. The Company?s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 60 countries, as well as 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 20 generic research and development centers operating mostly within certain manufacturing sites and 20 API manufacturing sites around the world. In January 2009, Phibro Animal Health Corporation completed the acquisition of the Abic Animal Health business from the Company.